Skip to main content
. 2014 Jul;51(1):143–154. doi: 10.1165/rcmb.2013-0360OC

Figure 2.

Figure 2.

Anti–RSV-G was effective in preventing AHR and airway inflammation after primary RSV infection when administered 2 days after infection. (A) Airway responsiveness to inhaled MCh. (B) BAL cellularity. (C) BAL fluid IFN-γ levels. (D) Virus titers in the lung. Results from three independent experiments with 12 mice per group are expressed as mean ± SD. *P < 0.05, **P < 0.01.